1. Home
  2. KZIA vs PBM Comparison

KZIA vs PBM Comparison

Compare KZIA & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZIA
  • PBM
  • Stock Information
  • Founded
  • KZIA 1994
  • PBM 1994
  • Country
  • KZIA Australia
  • PBM Canada
  • Employees
  • KZIA N/A
  • PBM 10
  • Industry
  • KZIA Biotechnology: Pharmaceutical Preparations
  • PBM
  • Sector
  • KZIA Health Care
  • PBM
  • Exchange
  • KZIA Nasdaq
  • PBM NYSE
  • Market Cap
  • KZIA 7.8M
  • PBM 5.3M
  • IPO Year
  • KZIA 1999
  • PBM N/A
  • Fundamental
  • Price
  • KZIA $1.29
  • PBM $1.37
  • Analyst Decision
  • KZIA Strong Buy
  • PBM
  • Analyst Count
  • KZIA 2
  • PBM 0
  • Target Price
  • KZIA $11.50
  • PBM N/A
  • AVG Volume (30 Days)
  • KZIA 5.5M
  • PBM 526.0K
  • Earning Date
  • KZIA 03-26-2025
  • PBM 02-02-2025
  • Dividend Yield
  • KZIA N/A
  • PBM N/A
  • EPS Growth
  • KZIA N/A
  • PBM N/A
  • EPS
  • KZIA N/A
  • PBM N/A
  • Revenue
  • KZIA $1,655,324.00
  • PBM N/A
  • Revenue This Year
  • KZIA $806.89
  • PBM N/A
  • Revenue Next Year
  • KZIA N/A
  • PBM N/A
  • P/E Ratio
  • KZIA N/A
  • PBM N/A
  • Revenue Growth
  • KZIA 248000.00
  • PBM N/A
  • 52 Week Low
  • KZIA $1.25
  • PBM $1.21
  • 52 Week High
  • KZIA $15.80
  • PBM $323.25
  • Technical
  • Relative Strength Index (RSI)
  • KZIA 39.50
  • PBM 37.76
  • Support Level
  • KZIA $1.31
  • PBM $1.21
  • Resistance Level
  • KZIA $2.64
  • PBM $1.59
  • Average True Range (ATR)
  • KZIA 0.24
  • PBM 0.24
  • MACD
  • KZIA 0.09
  • PBM 0.03
  • Stochastic Oscillator
  • KZIA 14.29
  • PBM 17.53

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: